Emmaus Life Sciences, Inc. (EMMA)
| Market Cap | 1.02M |
| Revenue (ttm) | 16.65M |
| Net Income (ttm) | -6.45M |
| Shares Out | 63.87M |
| EPS (ttm) | -0.10 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,116 |
| Average Volume | 3,734 |
| Open | 0.0150 |
| Previous Close | 0.0160 |
| Day's Range | 0.0150 - 0.0160 |
| 52-Week Range | 0.0001 - 0.1100 |
| Beta | 6.21 |
| RSI | 39.75 |
| Earnings Date | Mar 31, 2025 |
About Emmaus Life Sciences
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company’s lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its pipeline products include ELS001/ELS007, a pharmaceutical grade L-glutamine, which has completed phase 3 clinical trial to treat sickle cell ... [Read more]
Financial Performance
Financial StatementsNews
Emmaus Life Sciences Reports Improved Quarterly Financial Results
TORRANCE, Calif. , Nov. 19, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. ( OTCQB : EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today repo...
Emmaus Life Sciences Reports Quarterly Financial Results
TORRANCE, Calif. , Sept. 10, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC Markets: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today...
Emmaus Life Sciences Announces Willis C. Lee as Chief Executive Officer
TORRANCE, Calif. , July 23, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCMarkets: EMMA), a leader in sickle cell disease treatment, announced that Willis C.
Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program
TORRANCE, Calif. , July 12, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announ...
Emmaus Life Sciences Reports 2023 Financial Results
TORRANCE, Calif. , July 3, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reporte...
Emmaus Life Sciences Reports Delayed Filing of Annual Report
TORRANCE, Calif. , April 15, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, reported to...
Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico
TORRANCE, Calif. , Feb. 2, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease (SCD) treatment, today announced that it has received marketing authorization ...
Emmaus Life Sciences Reports Q3 2023 Financial Results
TORRANCE, Calif. , Nov. 14, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today report...
Emmaus Life Sciences Reports Management Changes
Principal Inventor of Endari® (L-glutamine oral powder) and Long-time Chairman and Chief Executive Officer Free to Purse New Projects Company Appoints Interim Co-Presidents to Focus on Core Business T...
Emmaus Life Sciences Reports Q2 2023 Financial Results
Record Net Revenues Contributed to Income from Operations Sixth Straight Quarterly Increase in Net Revenues TORRANCE, Calif. , Aug. 14, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a...
Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman
Sickle Cell Disease Treatment Commercially Available in Five GCC Countries TORRANCE, Calif. , July 13, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease tr...
Emmaus Life Sciences Receives Endari® Marketing Authorization from the Bahrain NHRA
TORRANCE, Calif. , May 31, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, announced today that it has received a Medicine Registration Certif...
Emmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update
TORRANCE, Calif. , May 15, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reporte...
Emmaus Life Sciences Provides Interim Shipment Data
TORRANCE, Calif. , April 3, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle ell disease treatment, announced today preliminary results for the 3 months ended March 31...
Emmaus Life Sciences Reports 2022 Financial Results and Provides Business Update
TORRANCE, Calif. , March 31, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today repor...
Dr. Niihara Meets with Local Indian Governor
Cites Large, Unserved Needs of Sickle Cell Disease Patients TORRANCE, Calif. , Dec. 20, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), announced today that Dr. Yutaka Niihara, Chairm...
Dr. Niihara Feted by Indian Government in Recognition of the Development of Endari®
Celebrity Event Hosted in Mumbai, India TORRANCE, Calif., Dec. 19, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), announced today that Dr. Yutaka Niihara, Chairman and Chief Executiv...
Endari® Receives Kuwaiti Marketing Authorization
Kuwait is Third Gulf Cooperation Council Country to Approve Endari ® TORRANCE Calif. , Dec. 7, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment,...
Emmaus Life Sciences Receives Endari® Marketing Authorization from the Qatar Ministry of Public Health
Company Receives First Major Purchase Order in Saudi Arabia TORRANCE, Calif. , Nov. 17, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announ...
Emmaus Life Sciences Reports Q3 2022 Financial Results and Provides Business Update
TORRANCE, Calif. , Nov. 14, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today report...
Emmaus Life Sciences Announces Collaboration with Kier (Junior) Spates to Share Personal Experience with Sickle Cell Disease and Endari®
Nationally Syndicated Radio Programming Will Educate and Support SCD Patients TORRANCE, Calif. , Sept. 28, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA) a commercial-stage biopharmaceu...
Emmaus Life Sciences Reports Q2 2022 Financial Results and Provides Business Update
TORRANCE, Calif. , Aug. 15, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today report...
Emmaus Life Sciences Announces Engagement of Strategic Business Relations and Professional Services Advisor
Acorn Management Partners Will Develop and Implement a Market Awareness Program Targeting Financial Professionals TORRANCE, Calif. , July 12, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: E...
Emmaus Life Sciences Reports Q1 2022 Financial Results and Provides Business Update
TORRANCE, Calif. , May 13, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reporte...
Emmaus Life Sciences to Present at Investor Conferences in May
TORRANCE, Calif. , April 26, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today ann...